- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Selexipag
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 15
- States / cities
- La Jolla, California • San Francisco, California • Torrance, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil, Non-Treprostinil PAH Medications
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Timeline
- 2019
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Santa Barbara, California + 7 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more